Primary CD34+ cells from VEXAS patients exhibited significantly higher sensitivity to both TAK‐243 and pevonedistat compared to cells from MDS patients and healthy controls as demonstrated by lower cell viabilities and higher levels of apoptosis. The gene discussed is CD34; the disease is myelodysplastic syndrome.